Mechanisms, Markers and Management of Hypercoagulable States

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 1-8

  Mannucci, Pier Mannuccio ^a   Tripodi, Armando ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

DDimer, F1+2; Hypercoagulable States; Thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; ENZYME PRECURSOR; PROTHROMBIN COMPLEX; WARFARIN;

BLOOD CLOTTING; CONFERENCE PAPER; ENZYME ACTIVATION; HUMAN; HYPERCOAGULABILITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGULATORY MECHANISM; THROMBOSIS;

BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; DISEASE SUSCEPTIBILITY; ENZYME ACTIVATION; ENZYME PRECURSORS; FEMALE; HUMANS; MALE; PREGNANCY; RISK FACTORS; THROMBOEMBOLISM;

EID: 0029960580     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217279     Document Type: Article

References (50)

1. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350.
2. Tytgat GN, Collen D, Verstrate M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest 1971; 50: 1690-1697.
3. Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005.
4. Martinez J, Shapiro SS, Holburn RR. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states. Blood 1973; 42: 35-46.
5. Boisclair MD. Lane DA. Philippou H. Esnouf MP. Sheikh S. Hunt B. Smith KJ. Mechanism of thrombin generation during surgery and cardiopulmonary Bypass. Blood 1993; 82: 3350-3357.
6. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemostas 1995; 74 7-17.
7. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor Vila in hemophilia A and B patients. Blood 1992; 80: 25-28.
8. Morrissey JH. Macik BG. Neuenschwander PF. Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993: 81: 734-744.
9. Bauer KA, Kass BL, ten Cate H, Bednarek MA. Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989: 74: 2007-2015.
10. Bauer KA. Kass BL. ten Cate H. Hawiger JJ. Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-736.
11. Aronson DL, Stevan L, Ball AP, Franza BR Jr, Finlayson JS. Generation of the combined prothrombin activation peptide (F 1.2) during the clotting of blood and plasma. J Clin Invest 1977: 60: 1410-1418.
12. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for F2/F1+2 fragment and the thrombin-antithrombin complex. Blood 1982; 59: 1086-1097.
13. Pelzer H, Schwarz A, Stuber W. Determination of human pro-thrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991: 65: 153-159.
14. Shi Q. Ruiz JA, Perez LM, Denis RF. Sio R, Alvarez D. Detection of prothrombin activation with a two-sites enzyme immunoassay for the fragment 1.2. Thromb Haemost 1989;62:165.
15. Hursting MJ. Butman BT. Steiner JP. Moore BM. Plank MC, Szewczyk KM. Bell ML. Dombrose FA. Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. Clin Chem 1993: 39: 583-591.
16. Nossel HL, Yudclman Y. Canfield RE, Butler VP Jr, Spanondis K. Wilner GD. Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54:43-53.
17. Nichols AB. Owen J. Kaplan KL. Sciacca RR. Canion PJ, Nossel HL. Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease. Blood 1982; 60: 650-654.
18. Nossel HL. Ti M, Kaplan KL. Spanondis K, Soland T, Butler VP Jr. The generation of fibrino peptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-1144.
19. Bauer KA. Kass BL, Beeler DL. Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 1984; 74: 2033-2041.
20. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-2348.
21. Pelzer H, Schwarz A, Heimburger N. Determination of thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-106.
22. España F. Vincente V, Tabernero D. Scharrer I. Griffin JH. Determination of plasma protein C inhibitor and of two activated protein C inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593-608.
23. España F. Gruber A. Heeb MJ. Hanson SR. Harker LA, Griffin JH. In vivo and in vitro com plexes of activated protein C with two inhibitors in baboons. Blood 1991: 77: 1754-1760.
24. Bauer KA. Mannucci PM. Gringeri A. Tradati F, Barzegar S, Kass BL. ten Cate H. Kestin AS, Brettler DB. Rosenberg RD. Factor IXa-Factor Villa-Cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79: 2039-2047.
25. ten Cate H. Bauer KA, Levi M. Edgington TS. Subbleu RD. Barzegar S, Kass BL. Rosenberg RD. The activation of factor X and prothrombin by recombinant factor Vila in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212.
26. Mannucci PM. Bauer KA. Gringeri A, Barzegar S, Bottasso B. Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients alter infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-2545.
27. Mannucci PM. Bauer KA. Gringeri A, Barzegar S, Santagostino E. Tradati F. Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991: 79: 606-611.
28. De Stefano V, Finazzi G. Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996; 87: 3531-3544.
29. Mannucci PM. Tripodi A, Bottasso B. Baudo F. Finazzi G, De Stefano V. Palareti G. Manotti C. Mazzucconi MG. Castaman G. Markers of procoagulant imbalance in patients with inherited thrombophilie syndromes. Thromb Haemostas 1992: 67: 200-202.
30. Demers C, Ginsberg JS. Henderson P. Ofosu FA. Weitz JI. Blajchman MA. Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemostas 1992; 67: 542-544.
31. Bauer KA. Broekmans AW, Bcrtina RM. Conard J. Horellou MH. Samama MM. Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71: 1418-1426.
32. Neri Serneri GG. Gensini GF. Abbate R. Laureano R. Parodi O. Is raised plasma fibrinopeptide A a marker of acute coronary insufficiency? Lancet 1980; 2: 982.
33. Neri Serneri GG, Gensini GF, Carnovali M, Prisco D. Rogasi PG, Casolo GC. Association bet ween time of increased fibrinopep-tide levels in plasma and episodes of spontaneous angina: a controlled prospective study. Am Heart J 1987; 113:672-8.
34. Theroux P. Latour JG. Leger-Gauthier C, De Lara J. Fibrino-peptide A and platelet factor 4 levels in unstable angina pectoris. Circulation 1987; 75: 156-162.
35. Merlini PA. Bauer KA. Oltrona L. Ardissino D. Cattanco M. Belli C, Mannucci PM. Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.
36. Bauer KA, Rosenberg RD. Assays of thrombin generation in humans with prethrombotic states. Thromb Haemost 1983; 50: 159.
37. Caine YG. Bauer KA. Barzegar S. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-395.
38. Bauer KA, ten Cate H, Barzegar S, Spriggs DR. Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procaoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74: 165-172.
39. Tripodi A, Mannucci PM, Chantarangkul V, Bottasso B, Arbini A, Della Bella S, Scorza R. Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol 1993; 84: 670-774.
40. Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-2963.
41. Francis R, Patch J, McGehee W, Crout F. Elevated prothrombin F 1+2 fragment in sickle cell disease: further evidence for activation of coagulation in the steady state. Blood 1990; 76:61a.
42. Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin com plex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 1990; 74: 471-479.
43. Boneu B, Bes G, Pelzer H, Sic P, Boccalon H. D-dimers, Thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombo-sis. Thromb Haemostas 1991; 65: 28-32.
44. Estivals M, Pelzer H, Sié P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effect of heparin treatment. Br J Haematol 1991; 78: 421-424.
45. Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sie' P, Bocca-lon H, Boneu B. Influence of Ions term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemostas 1993; 69: 302-305.
46. DVTENOX Study Group. Markers of hemostatic activation in acute deep venous thrombosis. Evolution during the first days of treatment. Thromb Haemostas 1993; 70: 909-914.
47. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80: 1535-1544.
48. Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "Mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F 1+2 levels. Blood 1992; 79: 2034-2038.
49. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic-changes that constitute the hypercoagulable state. Lancet 1991; 338: 1079.
50. Tripodi A, Chantarangkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1+2 values measured by two commercial ELISA methods: influence of different anti coagulants and standards. Thromb Haemostas 1994; 71: 605-608.